KENILWORTH, N.J.--(BUSINESS WIRE)--MSD, known as Merck (NYSE: MRK) in the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback